WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, August 28, 2006

Hide?	Set Name	Query	<u>Hit Count</u>
	DB=PGPE	B,USPT,DWPI; PLUR=YI	ES; OP=OR
	L3	Garcia-Martinez.in.	11
	L2	L1 and Proll.in.	2
	L1	Ramsdell.in.	153

END OF SEARCH HISTORY

```
PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/870,029
;
      FILING DATE: 17-APR-1992
    ATTORNEY/AGENT INFORMATION:
      NAME: Williams Ph.D., Kathleen A.
      REGISTRATION NUMBER: 34,380
      REFERENCE/DOCKET NUMBER: DFCC-230AX
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617) 542-2290
      TELEFAX: (617) 451-0313
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 205 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-233-005-2
                        100.0%; Score 591; DB 1; Length 205;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 1.5e-61;
 Matches 107; Conservative
                              0; Mismatches
                                               0; Indels
           1 PEVKVACSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNG 60
Qу
             Db
          21 PEVKVACSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNG 80
          61 SFDAPNERPYSLKIRNTTSCNSGTYRCTLODPDGORNLSGKVILRVT 107
QУ
             Db
          81 SFDAPNERPYSLKIRNTTSCNSGTYRCTLQDPDGQRNLSGKVILRVT 127
RESULT 3
US-08-428-943-2
; Sequence 2, Application US/08428943
; Patent No. 5766570
  GENERAL INFORMATION:
    APPLICANT: Tedder, Thomas F.
    APPLICANT: Zhou, Liang-Ji
    TITLE OF INVENTION: LYMPHOCYTE ACTIVATION ANTIGENS AND TITLE OF INVENTION: ANTIBODIES THERETO
    NUMBER OF SEQUENCES: 15
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Weingarten, Schurgin, Gagnebin & Hayes
      STREET: Ten Post Office Square
      CITY: Boston
      STATE: MA
      COUNTRY: US
      ZIP: 02109
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/428,943
      FILING DATE:
      CLASSIFICATION: 424
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 08/233,005
      FILING DATE: 25-APR-1994
    PRIOR APPLICATION DATA:
```

```
APPLICATION NUMBER: US 07/870,029
      FILING DATE: 17-APR-1992
    ATTORNEY/AGENT INFORMATION:
      NAME: Holliday C. Heine, Ph.D.
      REGISTRATION NUMBER: 34,346
      REFERENCE/DOCKET NUMBER: DFCC-230BX
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617) 542-2290
      TELEFAX: (617) 451-0313
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 205 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-428-943-2
                        100.0%; Score 591; DB 1; Length 205;
 Query Match
 Best Local Similarity
                        100.0%; Pred. No. 1.5e-61;
 Matches 107; Conservative
                               0; Mismatches
                                               0; Indels
                                                                Gaps
           1 PEVKVACSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNG 60
Qy
             21 PEVKVACSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNG 80
Db
          61 SFDAPNERPYSLKIRNTTSCNSGTYRCTLQDPDGQRNLSGKVILRVT 107
Qу
             Db
          81 SFDAPNERPYSLKIRNTTSCNSGTYRCTLODPDGQRNLSGKVILRVT 127
RESULT 4
US-09-016-649-2
; Sequence 2, Application US/09016649
 Patent No. 6068984
  GENERAL INFORMATION:
    APPLICANT: Tedder, Thomas F.
    APPLICANT: Zhou, Liang-Ji
    TITLE OF INVENTION: LYMPHOCYTE ACTIVATION ANTIGENS AND
    TITLE OF INVENTION: ANTIBODIES THERETO
    NUMBER OF SEQUENCES: 15
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Weingarten, Schurgin, Gagnebin & Hayes
      STREET: Ten Post Office Square
      CITY: Boston
      STATE: MA
      COUNTRY: US
      ZIP: 02109
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
;
      APPLICATION NUMBER: US/09/016,649
      FILING DATE:
      CLASSIFICATION:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US/08/428,943
      FILING DATE:
      APPLICATION NUMBER: US 08/233,005
      FILING DATE: 25-APR-1994
```

```
RESULT 4
AAW35105
     AAW35105 standard; protein; 205 AA.
ID
XX
     AAW35105;
AC
XX
DT
     23-MAR-1998
                 (first entry)
XX
DE
     CD38 protein.
XX
     CD38; human; immunoqlobulin; IqG; humoral response; antigen; vaccine;
KW
     dendritic cell; lymphoblastoid.
KW
XX
     Unidentified.
OS
XX
                     Location/Qualifiers
FH
     Key
FT
     Peptide
                     1. .19
                     /label= Signal
FT
FT
     Protein
                     20. .206
FT
                     /label= CD38
XX
PN
     WO9729781-A1.
XX
PD
     21-AUG-1997.
XX
PF
     13-FEB-1997;
                    97WO-US002350.
XX
PR
     15-FEB-1996;
                    96US-00601954.
PR
     27-JUN-1996;
                    96US-00673753.
PR
     26-SEP-1996;
                    96US-00720284.
XX
PA
    (IMMV ) IMMUNEX CORP.
XX
PΙ
    Armitage RJ, Fanslow WC,
                                Escobar C,
                                             Zappone J;
XX
DR
     WPI; 1997-424766/39.
     N-PSDB; AAT94927.
DR
XX
     Stimulating humoral response with antigen and CD83 protein or DNA - as
PT
PΤ
     adjuvant, providing a primary response similar to a normal secondary
PT
     response.
XX
PS
     Claim 2; Page 24-25; 35pp; English.
XX
CC
     A method has been developed for stimulating a humoral response by
CC
     administration of a CD83 DNA or protein and an antigen (Ag) in a carrier.
CC
     The present sequence represents CD38. The combination of Ag and CD38 DNA
CC
     or protein is used as a vaccine. Antibodies (Ab) against CD83, or other
CC
     CD83 antagonists, inhibit some antigen-specific responses, so can be used
CC
     to prevent undesirable responses; to prevent or treat autoimmune disease
CC
     (e.g. myasthenia gravis, multiple sclerosis and systemic lupus
CC
     erythematosus), transplant rejection, allergy and asthma, also to assay
CC
     CD83. The CD38 DNA may be inserted into an attenuated live virus or
CC
    bacterium vaccine strain. CD83 protein is used to raise Ab, as
CC
     immunoassay reagent and binding agent for affinity purification. CD83 (a
CC
     member of the immunoglobulin superfamily, expressed on the surface of
CC
     some dendritic and lymphoblastoid cells) stimulates production of Aq-
CC
     specific antibodies, i.e. is provides a primary response that
CC
     qualitatively and quantitatively resembles a secondary response
XX
```